Half-year report · Q2
2372.TEDINET S100UMR9
Period2024-04-01 → 2024-09-30
Filed2024-11-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥85m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥790m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥75m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥52m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥65m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥65m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥35.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥37.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥36.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.7bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥24.4bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥12.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥13.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥446m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥803m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥280m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥163m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥17m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-5.41 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.92 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.22 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 63
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥95m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥969m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥597m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥554m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥101m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥344m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥41m |
| jpcrp040300-q2r_E05352-000Drug Discovery Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥229m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥506m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥626m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥95m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥320m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥250m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥25m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥913m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥884m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥887m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥20m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥610m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥66m |
| jpcrp040300-q2r_E05352-000Drug Discovery Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥367m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥903m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥494m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥409m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥39m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥490m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.9bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 551
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1729000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -25000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1704000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -913000000 | JPY |
| Operating income | Prior1YTDDuration | 790000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 4301000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 3419000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | 597000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 506000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 8825000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 8830000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 8830000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 320000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 344000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | 554000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 626000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 1846000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1846000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -1846000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 4621000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 3764000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | 1152000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 1132000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 10671000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10676000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -1846000000 | JPY |
| Net sales | CurrentYTDDuration | 8830000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 1426000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | -41000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | -101000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | -229000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 95000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 1150000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -95000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1055000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -969000000 | JPY |
| Operating income | CurrentYTDDuration | 85000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-06 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第28期中（自 2024年４月１日 至 2024年９月30日） |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |